DCP Midstream (NYSE:DCP) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $0.54 by 140.74 percent. This is a 246.67 percent decrease over earnings of $0.15 per share from the same period last year.
Osmotica Pharmaceuticals’s Return On Capital Employed Insights
Osmotica Pharmaceuticals (NASDAQ:OSMT) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 70.39%, resulting in a loss of $20.18 million.
